{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:29:23Z","timestamp":1787758163346,"version":"build-2784847793"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of dexamethasone intravitreal implant in the treatment of relapsing posterior uveitis in patients with chronic recurrent Vogt\u2013Koyanagi\u2013Harada (VKH) disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a prospective study of 29 eyes of 16 patients with posterior uveitis in chronic recurrent VKH disease. All patients received previous systemic steroid and immunosuppressive regimens. All patients underwent a comprehensive ophthalmic examination, including best-corrected visual acuity (BCVA), Indocyanine green angiography (ICGA), fundus fluorescein angiography (FFA), and spectral-domain optical coherence tomography (SD-OCT). All patients underwent intravitreal injection with sustained-release dexamethasone 0.7 mg implant (Ozurdex\u00ae). Primary outcome measures included mean change in BCVA and central foveal thickness (CFT) at 24 months of follow-up compared to the baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At 24 month of follow-up, the mean BCVA improved from 0.82 \u00b1 0.13 to 0.38 \u00b1 0.06 logMAR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). The mean CFT reduced from 505 \u00b1 29 to 244 \u00b1 23 um (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). The mean intraocular pressure (IOP) changed from 15.1 \u00b1 2.2 to 16.9 \u00b1 3.1 mmHg with no significant value (\n                      <jats:italic toggle=\"yes\">P-<\/jats:italic>\n                      value = 0.0955). Twenty-one eyes (72.4%) received one injection, whereas eight eyes (27.6%) required two injections. The mean number of injections was 1.2 \u00b1 0.60. The mean follow-up time was 24.75 \u00b1 0.9 months. No serious ocular or systemic adverse events were noted during the follow-up period. Ocular hypertension was recorded in three (10.3%) eyes and controlled by IOP lowering medications. Cataract progression occurred in 11 (37.9%) eyes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our cohort highlights the beneficial effects of the dexamethasone implant of 0.7 mg in the treatment of VKH disease relapsing posterior uveitis improving visual acuity, reducing macular edema, and minimizing the burden of systemic steroids in this sample study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_260_22","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T06:28:32Z","timestamp":1657607312000},"page":"2465-2470","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Long-term efficacy of dexamethasone intravitreal implant in the treatment of Vogt-Koyanagi-Harada disease relapsing posterior uveitis"],"prefix":"10.4103","volume":"70","author":[{"given":"Tarek R","family":"Elhamaky","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Benha University, Benha, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bjophthalmol-2017-311707","article-title":"Decreased expression of A20 is associated with ocular Behcet's disease (BD) but not with Vogt-Koyanagi-Harada (VKH) disease","volume":"102","author":"He","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ajoc.2018.06.022","article-title":"Long term treatment with infliximab in pediatric Vogt-Koyanagi-Harada disease","volume":"11","author":"Budmann","year":"2018","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B3-20240828","first-page":"1419","article-title":"Catching the therapeutic window of opportunity in early initial-onset Vogt\u2013Koyanagi\u2013Harada uveitis can cure the disease","volume":"39","author":"Herbort","year":"2019","journal-title":"IntOphthalmol"},{"key":"B4-20240828","first-page":"1101","article-title":"Bilateral iris depigmentation and ocular hypotony as end-stage manifestations of untreated Vogt\u2013Koyanagi\u2013Harada disease","volume":"26","author":"Cuevas","year":"2018","journal-title":"OculImmunolInflamm"},{"key":"B5-20240828","first-page":"549","article-title":"Systemic steroid sparing effect of intravitreal dexamethasone implant in chronic noninfectious uveitic macular edema","volume":"33","author":"Fabiani","year":"2017","journal-title":"JOcular PharmacolTher"},{"key":"B6-20240828","first-page":"241","article-title":"Indocyanine green angiography guided management of Vogt-Koyanagi-Harada disease","volume":"6","author":"Bouchenaki","year":"2011","journal-title":"JOphthalVis Res"},{"key":"B7-20240828","first-page":"279","article-title":"Outcomes of Vogt-Koyanagi-Harada disease:A subanalysis from a randomized clinical trial of antimetabolite therapies","volume":"168","author":"Shen","year":"2016","journal-title":"AmJOphthalmol"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1111\/aos.12127","article-title":"Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids","volume":"91","author":"Abu El-Asrar","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"B9-20240828","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00417-014-2904-z","article-title":"High rate of clinical recurrence in patients with Vogt\u2013Koyanagi\u2013Harada disease treated with early high-dose corticosteroids","volume":"253","author":"Sakata","year":"2015","journal-title":"Graefes ArchClin Exp Ophthalmol"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/aos.13189","article-title":"Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of'sunset glow fundus'in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease","volume":"95","author":"El-Asrar","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"B11-20240828","first-page":"545","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"ArchOphthalmol"},{"key":"B12-20240828","first-page":"1","article-title":"Vogt-Koyanagi-Harada disease","volume":"62","author":"O'Keefe","year":"2017","journal-title":"SurvOphthalmol"},{"key":"B13-20240828","first-page":"29","article-title":"Vogt-Koyanagi-Harada disease:Review of a rare autoimmune disease targeting antigens of melanocytes","volume":"11","author":"Lavezzo","year":"2016","journal-title":"OrphanetJRare Dis"},{"key":"B14-20240828","first-page":"462","article-title":"Intraoperative dexamethasone implant in uveitis patients with cataract undergoing phacoemulsification","volume":"21","author":"Gupta","year":"2013","journal-title":"OculImmunolInflamm"},{"key":"B15-20240828","first-page":"639","article-title":"The effects of repeated Ozurdex injections on ocular hypertension","volume":"12","author":"Bahadorani","year":"2018","journal-title":"ClinOphthalmol"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12824","article-title":"Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis","volume":"1358","author":"Whitcup","year":"2015","journal-title":"Ann N YAcad Sci"},{"key":"B17-20240828","first-page":"1136","article-title":"Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis:Indications, outcomes, and reinjection frequency","volume":"158","author":"Zarranz-Ventura","year":"2014","journal-title":"AmJOphthalmol"},{"key":"B18-20240828","first-page":"647","article-title":"Revised diagnostic criteria for Vogt-Koyanagi-Harada disease:Report of an international committee on nomenclature","volume":"131","author":"Read","year":"2001","journal-title":"AmJOphthalmol"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/eye.2008.89","article-title":"Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease","volume":"23","author":"Lai","year":"2009","journal-title":"Eye"},{"key":"B21-20240828","first-page":"84","article-title":"Vogt-Koyanagi-Harada disease:Novel insights into pathophysiology, diagnosis, and treatment","volume":"52","author":"Du","year":"2016","journal-title":"ProgRetinEye Res"},{"key":"B22-20240828","first-page":"1044","article-title":"Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography","volume":"152","author":"Sugar","year":"2011","journal-title":"AmJOphthalmol"},{"key":"B23-20240828","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/eye.2014.129","article-title":"Evaluation of pain during intravitreal Ozurdex injections vs intravitreal bevacizumab injections","volume":"28","author":"Moisseiev","year":"2014","journal-title":"Eye"},{"key":"B24-20240828","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","article-title":"Safety of intravitreal dexamethasone implant (Ozurdex):the SAFODEX study. Incidence and risk factors of ocular hypertension","volume":"37","author":"Malcl\u00e8s","year":"2017","journal-title":"Retina"},{"key":"B25-20240828","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12348-011-0027-9","article-title":"Rituximab in refractory Vogt\u2013Koyanagi\u2013Harada disease","volume":"1","author":"Dolz-Marco","year":"2011","journal-title":"JOphthalmic InflammInfect"},{"key":"B26-20240828","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00417-010-1477-8","article-title":"Intravitreal bevacizumab injection for persistent serous retinal detachment associated with Vogt\u2013Koyanagi\u2013Harada disease","volume":"249","author":"Park","year":"2011","journal-title":"Graefe's Arch ClinExp Ophthalmol"},{"key":"B27-20240828","first-page":"550","article-title":"Diagnosis and classification of Vogt\u2013Koyanagi\u2013Harada disease","volume":"13","author":"sakata","year":"2014","journal-title":"AutoimmunRev"},{"key":"B28-20240828","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1111\/j.1755-3768.2010.02055.x","article-title":"Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt\u2013Koyanagi\u2013Harada disease","volume":"89","author":"Errera","year":"2011","journal-title":"Acta Ophthalmologica"},{"key":"B29-20240828","first-page":"835","article-title":"Results of intravitreal dexamethasone implant 0.7 mg (Ozurdex\u00ae) in non-infectious posterior uveitis","volume":"8","author":"Yap","year":"2015","journal-title":"IntJOphthalmol"},{"key":"B30-20240828","first-page":"1109","article-title":"Interventions for the treatment of uveitic macular edema:A systematic review and meta-analysis","volume":"7","author":"Karim","year":"2013","journal-title":"ClinOphthalmol (Auckland, NZ)"},{"key":"B31-20240828","first-page":"80","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"InvestigOphthalmolVisSci"},{"key":"B32-20240828","first-page":"1156","article-title":"Intravitreal dexamethasone implants for non-infectious uveitis","volume":"47","author":"McCartney","year":"2019","journal-title":"ClinExpOphthalmol"},{"key":"B33-20240828","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ophtha.2014.04.012","article-title":"Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation","volume":"121","author":"Cao","year":"2014","journal-title":"Ophthalmology"},{"key":"B34-20240828","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1159\/000485318","article-title":"IntralenticularOzurdex\u00ae\u2013one year later","volume":"8","author":"Regan","year":"2017","journal-title":"Case RepOphthalmol"},{"key":"B35-20240828","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/eye.2014.18","article-title":"Accidental insertion of dexamethasone implant into the crystalline lens\u201412 months follow-up","volume":"28","author":"Chhabra","year":"2014","journal-title":"Eye"},{"key":"B36-20240828","first-page":"57","article-title":"Treatment chronic macular edema in Vogt-Koyanagi Harada syndrome with dexamethasone intravitreal implant:Description of three case","volume":"2","author":"Pacella","year":"2015","journal-title":"Senses Sci"},{"key":"B37-20240828","first-page":"1145","article-title":"Bilateral dexamethasone intravitreal implant in a young patient with Vogt-Koyanagi-Harada disease and refractory uveitis","volume":"34","author":"Latronico","year":"2015","journal-title":"ClinRheumatol"},{"key":"B38-20240828","first-page":"1589","article-title":"Intravitreal triamcinolone acetonide for rebound phenomenon after high-dose intravenous steroid treatment in Vogt-Koyanagi-Harada disease","volume":"5","author":"Byon","year":"2011","journal-title":"ClinOphthalmol (Auckland, NZ)"},{"key":"B39-20240828","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3109\/09273940903267936","article-title":"Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease","volume":"17","author":"Khalifa","year":"2009","journal-title":"Ocular ImmunolInflamm"},{"key":"B40-20240828","first-page":"1423","article-title":"Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant","volume":"4","author":"Myung","year":"2010","journal-title":"ClinOphthalmol (Auckland, NZ)"},{"key":"B41-20240828","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.ophtha.2011.02.042","article-title":"Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis","volume":"118","author":"Bollinger","year":"2011","journal-title":"Ophthalmology"},{"key":"B42-20240828","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/09273948.2015.1132738","article-title":"Treatment of non-infectious uveitic macular edema with the intravitreal dexamethasone implant","volume":"25","author":"Nobre-Cardoso","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"B43-20240828","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/09273948.2016.1215472","article-title":"Iluvien implantation for uveitis and uveitic macular edema","volume":"26","author":"Reddy","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"B44-20240828","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1097\/IAE.0000000000001094","article-title":"Fluocinolone acetonide implant for Vogt\u2013Koyanagi\u2013Harada disease","volume":"36","author":"Heo","year":"2016","journal-title":"Retina"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_260_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:04:22Z","timestamp":1787756662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_260_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_260_22","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"assertion":[{"value":"2022-02-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}